Serkies Krystyna, Sinacki Marcin, Jassem Jacek
Oncology and Radiotherapy Department, Medical University of Gdańsk, Poland.
Contemp Oncol (Pozn). 2013;17(1):14-9. doi: 10.5114/wo.2013.33768. Epub 2013 Mar 15.
The efficacy of the second-line chemotherapy commonly used in both relapsed ovarian cancer patients and those with primary treatment failure remains unsatisfactory. This therapy has a small effect on survival, whereas associated toxicity may diminish the patient's quality of life. Hormonal factors play a role in ovarian tumorigenesis, and inhibition of the stimulating effects of estrogens may exert a clinical benefit. The role of hormonal therapy as a palliative therapeutic alternative for ovarian cancer remains undetermined. This modality may result in long-term stabilization of disease in individual patients and less frequently in tumor remission. In this article the role of hormonal factors and recent literature of various forms of hormonal therapy for ovarian cancer are presented.
常用于复发性卵巢癌患者和初始治疗失败患者的二线化疗疗效仍不尽人意。这种疗法对生存率的影响较小，而相关毒性可能会降低患者的生活质量。激素因素在卵巢肿瘤发生中起作用，抑制雌激素的刺激作用可能会带来临床益处。激素疗法作为卵巢癌姑息性治疗选择的作用仍未确定。这种治疗方式可能会使个别患者的病情长期稳定，较少出现肿瘤缓解。本文介绍了激素因素的作用以及各种形式的卵巢癌激素治疗的最新文献。
